Unique protein structures could hold the key to treatment for Parkinson's disease
Parkinson's Disease Therapies Targeting Alpha Synuclein
IJMS, Free Full-Text
PDF) Alpha-Synuclein in Parkinson's Disease: From Pathogenetic Dysfunction to Potential Clinical Application
CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson's disease: a study in LRRK2 mutation carriers, Translational Neurodegeneration
IJMS, Free Full-Text
Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets
The quest for a disease-modifying drug for Parkinson's disease continues - Drug Discovery and Development
Frontiers Parkinson's Disease: A Nanotheranostic Approach Targeting Alpha- Synuclein Aggregation
Pathological Pathways and Alpha-Synuclein in Parkinson's Disease: A View from the Periphery
PDF] The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease
The microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic